<DOC>
	<DOCNO>NCT02730325</DOCNO>
	<brief_summary>The effect serum-derived bovine immunoglobulin/protein isolate ( SBI ) evaluate compare match placebo two distinct patient population : I. Hospitalized ulcerative colitis ( UC ) patient test positive Clostridium difficile ( C. difficile ) time admission receive vancomycin . II . Hospitalized UC patient test negative C. difficile time admission .</brief_summary>
	<brief_title>To Evaluate Impact SBI C. Difficile Hospitalized UC Patients</brief_title>
	<detailed_description>The effect serum-derived bovine immunoglobulin/protein isolate ( SBI ) evaluate compare match placebo two distinct patient population : I. Hospitalized ulcerative colitis ( UC ) patient test positive Clostridium difficile ( C. difficile ) time admission receive vancomycin . Primary Objective : • To evaluate effect SBI time ( # day ) resolution diarrhea , define consecutive 24 hour period form bowel movement ( Bristol Stool Scale ( BSS ) ≤ 4 ) patient population Secondary Objectives : - To evaluate ability SBI decrease incidence recurrent C. difficile infection ( CDI ) follow successful treatment vancomycin . - To evaluate effect SBI UC status - To evaluate effect SBI nutritional status - To evaluate safety tolerability SBI - To evaluate effect SBI subject ' quality life ( QOL ) - To investigate effect SBI fecal microbiome - To evaluate length hospitalization ( time hospitalization time discharge ) II . Hospitalized UC patient test negative C. difficile time admission . Primary Objective : • To evaluate effect SBI time ( # day ) resolution diarrhea , define consecutive 24 hour period form bowel movement ( Bristol Stool Scale ( BSS ) ≤ 4 ) patient population Secondary Objectives : - To evaluate effect SBI decrease incidence CDI - To evaluate effect SBI UC status - To evaluate effect SBI nutritional status - To evaluate safety tolerability SBI - To evaluate effect SBI subject ' QOL - To investigate effect SBI fecal microbiome - To evaluate length hospitalization ( time hospitalization time discharge )</detailed_description>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Diagnosis UC confirm colonoscopy histology . Confirmed active UC upon hospital admission , define partial Mayo Score ≥ 3 stool frequency subscore ≥ 2 . Concomitant therapy UC permit . Subjects instructed make medication change hospital discharge first discuss Investigator . Eligible subject assign one two different independent patient group base C. difficile status determine clinical symptom diarrhea laboratory test : either polymerase chain reaction ( PCR ) assay glutamate dehydrogenase ( GDH ) screen test use two threestep algorithm subsequent toxin A B EIA test . Subjects history constipation within week screen visit ; serious hepatic , renal , cardiovascular , neurological hematological disorder opinion Investigator . Subjects history drug alcohol abuse , history psychiatric disorder , know allergy hypersensitivity beef component SBI . Subjects history antibiotic treatment within 4 week prior enrollment . Subjects use antidiarrheal medication ( e.g. , loperamide bismuth subsalicylate ) . Note : antidiarrheal medication prohibit throughout study . Subjects admit hospital 48 hour prior enrollment . Women pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CDI</keyword>
	<keyword>C. diff</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>UC</keyword>
	<keyword>IBD</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>